Aimmune Therapeutics (NASDAQ:AIMT) has been assigned a $79.00 price target by equities research analysts at Wedbush in a report issued on Thursday, TipRanks reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Wedbush’s price target suggests a potential upside of 326.80% from the company’s current price.
Several other research firms have also commented on AIMT. Zacks Investment Research upgraded DLH from a “sell” rating to a “hold” rating in a research report on Tuesday. BidaskClub upgraded Zillow Group from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 2nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $27.00 price target on shares of Spero Therapeutics in a research report on Thursday, May 9th. Credit Suisse Group dropped their price target on Athene from $67.00 to $57.00 and set an “outperform” rating for the company in a research report on Tuesday, May 21st. Finally, ValuEngine upgraded Zillow Group from a “hold” rating to a “buy” rating in a research report on Thursday. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $46.43.
AIMT traded down $1.38 on Thursday, hitting $18.51. The company had a trading volume of 2,405,950 shares, compared to its average volume of 573,287. The firm has a market cap of $1.31 billion, a P/E ratio of -5.04 and a beta of -0.06. Aimmune Therapeutics has a 12-month low of $16.95 and a 12-month high of $36.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.65 and a current ratio of 7.65. The company’s fifty day moving average is $20.23.
Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.87) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.07. On average, sell-side analysts anticipate that Aimmune Therapeutics will post -3.77 EPS for the current year.
Large investors have recently made changes to their positions in the business. Cable Hill Partners LLC boosted its position in shares of Aimmune Therapeutics by 81.7% during the first quarter. Cable Hill Partners LLC now owns 1,112 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 500 shares during the period. Manchester Capital Management LLC purchased a new position in shares of Aimmune Therapeutics during the 1st quarter valued at approximately $27,000. Pearl River Capital LLC purchased a new position in Aimmune Therapeutics in the 1st quarter valued at $28,000. Marshall Wace North America L.P. purchased a new position in Aimmune Therapeutics in the 1st quarter valued at $32,000. Finally, Advisor Group Inc. raised its holdings in shares of Aimmune Therapeutics by 84.6% during the 4th quarter. Advisor Group Inc. now owns 1,737 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 796 shares during the period. Institutional investors and hedge funds own 76.12% of the company’s stock.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Further Reading: Cost of Debt
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.